Table 3.

Associations of SIAH2 protein levels with clincopathological factors of 245 patients from the MBC-cohort

Characteristic	N	%*	Low SIAH2 protein expression**	%	High SIAH2 protein expression***	%	P-valueα
All patients	245	100	159	65	86	35
Age (years)
≤ 40	17	7	8	5	9	10	0.003β
41-55	78	32	44	28	34	40
56-70	88	36	60	38	28	33
> 70	62	25	47	30	15	17
Menopausal status
Premenopausal	66	27	33	21	33	38	0.003
Postmenopausal	179	73	126	79	53	62
Adjuvant chemotherapy
No	148	60	97	61	51	59	0.790
Yes	80	33	50	31	30	35
Lymph nodes involved
0	86	35	49	31	37	43	0.107
1-3	71	29	52	33	19	22
> 3	83	34	53	33	30	35
Differentiation grade#
1	37	15	33	21	4	5	< 0.001
2	131	53	92	58	39	45
3	77	31	34	21	43	50
Tumor histology
IDC	210	86	134	84	76	88	0.599
ILC	20	8	15	9	5	6
Other	15	6	10	6	5	6
PgR status†
Negative	62	25	40	25	22	26	0.942
Positive	183	75	119	75	64	74
HER2/neu status†
Negative	197	80	140	88	57	66	< 0.001
Positive	48	20	19	12	29	34
Dominant site of relapse
Viscera	92	38	62	39	30	35	0.005
Bone	124	51	86	54	38	44
Soft tissue	29	12	11	7	18	21
Disease-free survival (years)
≤ 1	36	15	25	16	11	13	0.611
1-3	118	48	73	46	45	52
> 3	91	37	61	38	30	35

Abbreviations: IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; PgR, progesterone receptor.

^*Due to missing information numbers do not always add up to 100%.

^**SIAH2 negative defined as ≤ 20% cells positive for SIAH2 staining.

^***SIAH2 positive defined as > 20% cells positive for SIAH2 staining.

^α P for Pearson’s Chi-squared test;

^βMann-Whitney U test.

^#According to the Bloom-Richardson score.

^†As retrieved from TMA.